Skip to main content
4DMEDICAL LIMITED logo

4DMEDICAL LIMITED — Investor Relations & Filings

Ticker · 4DX ISIN · AU0000095416 LEI · 9845000A8F12A6A6FD75 ASX Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2026-01-21 Transaction in Own Shar…
Country AU Australia
Listing ASX 4DX

About 4DMEDICAL LIMITED

https://4dmedical.com/

4DMedical Limited develops non-invasive respiratory imaging solutions centered on its proprietary XV Technology. This platform utilizes advanced algorithms to transform standard X-ray sequences into four-dimensional quantitative data, visualizing regional lung function in motion. The flagship XV Lung Ventilation Analysis Software (XV LVAS) provides clinicians with detailed maps of airflow distribution throughout the respiratory cycle, facilitating the early detection and monitoring of chronic conditions such as COPD, asthma, and interstitial lung disease. By providing objective, high-resolution insights into lung ventilation without the limitations of traditional pulmonary function tests, the company's cloud-based diagnostic tools aim to improve clinical workflows and patient management. The integration of artificial intelligence further enhances its capability to deliver precise, automated lung tissue analysis.

Recent filings

Filing Released Lang Actions
Notification of cessation of securities - 4DX 4 pages 14.9KB
Transaction in Own Shares Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cessation of certain securities (options) for 4DMedical Limited. It includes specific information about the securities that have ceased, the reason for cessation (expiry of options), and the updated issued capital following these changes. The document is a formal announcement to the ASX regarding changes in the company's issued securities, specifically the cessation of certain options. This type of document corresponds to a notification about changes in share capital or securities status rather than a full financial report or earnings release. Given the content and nature, this fits best under 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares or changes in securities such as expiry or cessation of options. The document length is 4405 characters, which is consistent with a detailed announcement rather than a full report. Therefore, the classification is POS with high confidence.
2026-01-21 English
Change of Director's Interest Notice AF, JS and JL 11 pages 527.3KB
Director's Dealing Classification · 100% confidence The document is an Appendix 3Y filing, which is a Change of Director's Interest Notice as per ASX Listing Rule 3.19A.2. It details changes in shareholdings and option exercises by company directors Andreas Fouras, Julian Sutton, and John Livingston. The content focuses on directors' personal share transactions and disclosures of their interests in securities. There is no financial performance data, earnings information, or management discussion. The document is regulatory in nature, specifically reporting insider transactions by directors. According to the filing definitions, this corresponds to Director's Dealing (DIRS). The document length and detail confirm it is the actual notice, not just an announcement of a report. Therefore, the correct classification is DIRS with high confidence.
2026-01-21 English
Application for quotation of securities - 4DX 5 pages 16.7KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX. It details the number and type of securities to be quoted, issue dates, and references a previous Appendix 3B announcement related to the securities issuance. The document is a formal announcement related to capital changes, specifically the quotation of newly issued securities. It is not a financial report, earnings release, or management discussion. It fits the category of announcements regarding new share issues or capital changes.
2026-01-20 English
Investor Presentation 20 pages 1.9MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by 4DMedical Limited dated January 2026. It contains extensive information about the company's products, market opportunities, partnerships, technology, and strategy. The text explicitly states it is a presentation prepared for information purposes and not an offer or financial product advice. There is no indication of it being a formal financial report like an Annual Report (10-K) or Interim Report (IR). It is not a transcript of a call, nor an audit or legal proceeding report. The content is consistent with an Investor Presentation (IP) as it focuses on company strategy, market positioning, product details, and growth opportunities. The length (15,000 characters) and detailed content support this classification rather than a brief factsheet or announcement. Therefore, the document is best classified as an Investor Presentation (IP).
2026-01-18 English
Application for quotation of securities - 4DX 9 pages 27.0KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and contains detailed information about securities issued, transferred, or re-classified due to options being exercised or convertible securities being converted. It includes specifics such as issue dates, number of securities, issue prices, and the resulting issued capital following quotation. The document is a formal application to the ASX (Australian Securities Exchange) for the quotation of these securities. This type of filing corresponds to announcements regarding new share issues or capital changes, specifically the application for quotation of securities after issuance or conversion. Therefore, the document fits the category of 'Share Issue/Capital Change' (SHA). The document length is substantial (over 12,000 characters) and contains detailed data, confirming it is not merely an announcement of a report but the actual filing for quotation of securities.
2026-01-15 English
4DMedical completes $150 million institutional placement 4 pages 337.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 15 January 2026 from 4DMedical Limited regarding the completion of a $150 million institutional placement. It details the capital raise, share issuance, option exercises by executives, and use of proceeds. The content focuses on financing activities, including share placements, block trades, and option exercises, with no financial statements or quarterly results presented. The document is a capital/financing update rather than a full financial report or earnings release. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2026-01-14 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.